Document Detail


Domperidone, a DA2-specific dopamine antagonist, has no effect on the renal or haemodynamic response to atrial natriuretic peptide in man.
MedLine Citation:
PMID:  2974769     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. Animal experiments have suggested that the renal effects of atrial natriuretic peptide (ANP) are dependent on dopaminergic activation, predominantly of the DA1-receptor. In man, there is evidence of dependence on the DA2-receptor for the natriuresis produced by central blood volume expansion. 2. Six normal volunteers underwent infusions of alpha-human ANP preceded by domperidone (a DA2-antagonist) or placebo. Eight volunteers underwent a 3 h period of 10 degrees head-down tilt also preceded by domperidone or placebo. 3. Both the ANP infusion and head-down tilt produced a significant diuresis and natriuresis, neither of which was antagonized by the presence of domperidone. 4. The ANP infusion significantly reduced diastolic blood pressure and produced significant increases in the Doppler-measured aortic blood velocity variables of peak velocity and maximal acceleration. Domperidone had an independent effect of increasing blood pressure but did not appear to have a specific interaction with the haemodynamic effects of ANP. 5. Head-down tilt reduced mean arterial pressure and heart rate and increased maximal acceleration. Again, an independent effect of domperidone was seen on blood pressure. Heart rate and maximal acceleration showed similar changes in the presence of domperidone. 6. Domperidone does not antagonize the renal or haemodynamic effects of ANP and if dopaminergic activation is necessary for the renal action of ANP it is unlikely to be mediated by the DA2-receptor.
Authors:
M J Allen; V T Ang; E D Bennett
Related Documents :
2941539 - The character of the atrial natriuretic response: pressure and volume effects.
2943959 - Atrial natriuretic factor increases hematocrit and decreases plasma volume in nephrecto...
677029 - Three cases of hypotension and syncope with ventricular pacing: possible role of atrial...
19386989 - B-type natriuretic peptide 8-32, which is produced from mature bnp 1-32 by the metallop...
2918169 - Assessment of right atrial pressure-volume relations in patients with and without an at...
2136969 - Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure.
11320369 - Adept: addition of the at1 receptor antagonist eprosartan to ace inhibitor therapy in c...
7569659 - Manometric rhinometry: a new method of measuring nasal volume.
18297189 - Association of apoe polymorphisms with prevalent hypertension in 1406 older adults: the...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  75     ISSN:  0143-5221     ISO Abbreviation:  Clin. Sci.     Publication Date:  1988 Dec 
Date Detail:
Created Date:  1989-02-21     Completed Date:  1989-02-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  569-75     Citation Subset:  IM; S    
Affiliation:
Department of Medicine One, St George's Hospital Medical School, London.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Atrial Natriuretic Factor / pharmacology*
Blood Pressure / drug effects
Diuresis / drug effects
Domperidone / pharmacology*
Hemodynamics / drug effects*
Humans
Kidney / drug effects*
Posture
Receptors, Dopamine / drug effects*
Receptors, Dopamine D2
Chemical
Reg. No./Substance:
0/Receptors, Dopamine; 0/Receptors, Dopamine D2; 57808-66-9/Domperidone; 85637-73-6/Atrial Natriuretic Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study.
Next Document:  Electrocardiographic diagnosis of left ventricular hypertrophy: influence of body build.